Stock Price Quote

SYNCOM FORMULATIONS (INDIA) LTD.

NSE : SYNCOMFBSE : 524470ISIN CODE : INE312C01025Industry : Pharmaceuticals & DrugsHouse : Private
BSE18.16-0.23 (-1.25 %)
PREV CLOSE ( ) 18.39
OPEN PRICE ( ) 18.40
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 462187
TODAY'S LOW / HIGH ( )17.70 18.51
52 WK LOW / HIGH ( )11 27.94
NSE18.12-0.27 (-1.47 %)
PREV CLOSE( ) 18.39
OPEN PRICE ( ) 18.40
BID PRICE (QTY) 18.12 (14135)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1492774
TODAY'S LOW / HIGH( ) 17.70 18.49
52 WK LOW / HIGH ( )10.95 27.9
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 21-06 1988
Management Info
Kedarmal Bankda - Chairman Vijay Shankarlal Bankda - Managing Director
Registered Office

Address 7 Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E),
Mumbai,
Maharashtra-400093

Phone 022 30887744 / 54

Email sfil87@syncomformulations.com

Website www.sfil.in

Registrars Details
Ankit Consultancy Pvt Ltd
Plot No 60,Electronic Complex,Pardeshipura,Indore
Listing : BSE, NSE

NEWS

02Jul Syncom Formulations (India) informs ab
Syncom Formulations (India) has informed that the Share Transfer Agent o..
09May Syncom Formulations (India) submits bo
Syncom Formulations (India) has informed that pursuant to Regulation 29(..
05Apr Syncom Formulations (India) informs ab
Syncom Formulations (India) has informed that it enclosed Certificate fo..
26Feb Syncom Formulations (India) informs ab
Syncom Formulations (India) has informed that both the Stock Exchanges,..
29Aug Syncom Formulations (India) informs ab
Syncom Formulations (India) has informed that the 35th Annual General Me..

Financials

in Millions
QTR Sep 24 ANNUAL 24
Net Profit109.5236.24
Gross Profit 146.49 317.6
Operating Profit 161.13409.55
Net Sales 1014.922583.6

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE)
peergroup  13869.35 (5.10%)
M.Cap ( in Cr)17794.22
Astrazeneca Pharma I (BSE)
peergroup  6967.40 (2.75%)
M.Cap ( in Cr)17418.50
Abbott India (BSE)
peergroup  27745.95 (0.38%)
M.Cap ( in Cr)58958.21
NGL Fine-Chem (BSE)
peergroup  1758.50 (2.53%)
M.Cap ( in Cr)1086.41
Sun Pharma Inds. (BSE)
peergroup  1798.00 (2.05%)
M.Cap ( in Cr)431400.43

Shareholding Pattern

PROMOTERS 50.57%
NON-INSTITUTION 49.3%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Syncom Formulations (India) Ltd.

Syncom Formulations (India) Ltd. was incorporated in the year 1988. Its today's share price is 18.16. Its current market capitalisation stands at Rs 1707.04 Cr. In the latest quarter, company has reported Gross Sales of Rs. 2583.6 Cr and Total Income of Rs.2714.6 Cr. The company's management includes Ankit Jain, Ritesh Kumar Lunkad, Ruchi Jindal, Rinki Bankda, Vijay Shankarlal Bankda, Kedarmal Bankda, Vaishali Agrawal.

It is listed on the BSE with a BSE Code of 524470 , NSE with an NSE Symbol of SYNCOMF and ISIN of INE312C01025. It's Registered office is at 7 Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E)Mumbai-400093, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Sanjay Mehta & Associates, SP Moondra & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.